Music Activity, Biofeedback sensors and Artificial Intelligence = Window to Cognitive Health.
Music, notably piano playing, involves multiple sensory processing, comprehension, quasi-simultaneous decision making and action execution. Simply put, it is one of the best ways to evaluate brain functions.
Our Products:
1) Ipsilon Cognitive Assessment Test
We have developed our cognitive assessment test (prototype being tested, as of August 2018).
What it does: evaluate impulsiveness, learning capability based on working memories.
What inputs/ outputs it assesses: comprehension (visuo-spatial/motor encoding) and finger responses.
What advantage?: eliminates language biases. Elicit multi-sensory responses, monitoring capability of many brain regions.
What value proposition?: compatible to research-grade biofeedback stimuli, can be combined with EEG and eye tracking.
Product availability: as an app (software as service) for tablets, estimated to be commercially available in 1Q, 2019.
2) Digital Biomarkers = Ipsilon Cognitive Test combined with Biofeedback data analysis algorithms
We are developing machine-learning algorithms to create digital biomarkers, when biofeedback (EEG & eye tracking) devices are used together with our Ipsilon Cognitive Test.
Targeted conditions:
Dementia, Alzheimer's Disease; Attention Deficit Hyperactivity Disorder (ADHD);
Parkinson's Disease; mTBI (concussion) and CTE (chronic traumatic encephalopathy);
Schizophrenia; Pharmaceuticals' drug R&Ds for neurodegenerative diseases and evaluating their cognitive impacts.
What it does: create user's cognitive profile in comparison to Average (control group) and illness-specific biomarkers.
What do users get?: Individual cognitive data into a profile as well as risk assessment how close their responses are to illness-specific biomarkers.
What do your digital biomarkers do?: we create illness-specific biofeedback data into comparable patterns by algorithms.
What is your advantage?: Cognitive responses reveal neurological and neuropsychiatric abnormalities at much earlier stage than structural abnormalities revealed by medical imaging techniques (e.g. MRI, PET).
Side effect?: No. Non-invasive.
When available?: R&D planned for January 2019 for a year with the partnership with another startup and clinical institution, expected availability for further clinical trials in 1Q, 2020.
3) Ipsilon Cognitive Training
Using the Ipsilon Cogntitive Test with our rhythmic stimulation training, we help reduce anxiety with specific illnesses and help train visual attention.
What it does: help reduce anxiety of specific neurological and neuropsychiatric conditions. For average users, it helps increase visual attention.
What does it use?: rhythmic stimulation at specific frequency.
Any side effects?: No. Non-invasive.
How do you know its efficacy?: used together with EEG, the calming effect is confirmed by users' brainwave responses.
Target conditions: PTSD, Anxieties due to neurological and neuropsychiatric conditions mentioned in 2).
When available?: R&D planned from January 2019 for a year with the same partnership mentioned in 2). Expected to deliver in 1Q, 2020.
Our One Pager and Investor Deck are available upon request.
One-pager can be seen at Slideshare of Yayoi Sakaki, Founder and inventor.
We are in preparation for patent filing with our models and methodologies.
We are/ have been mentored at incubator/accelerator at:
HighTechXL accelerator, Eindhoven, The Netherlands (http://www.hightechxl.com/), September 4 to December 6, 2017
ENDuRE Project (University of Pisa, www.endureproject.eu/), May 30, 2016 to June 11, 2016
Erasmus Center for Entrepreneurship (http://ece.nl/), May 6, 2016 to July 1, 2016
Music, notably piano playing, involves multiple sensory processing, comprehension, quasi-simultaneous decision making and action execution. Simply put, it is one of the best ways to evaluate brain functions.
Our Products:
1) Ipsilon Cognitive Assessment Test
We have developed our cognitive assessment test (prototype being tested, as of August 2018).
What it does: evaluate impulsiveness, learning capability based on working memories.
What inputs/ outputs it assesses: comprehension (visuo-spatial/motor encoding) and finger responses.
What advantage?: eliminates language biases. Elicit multi-sensory responses, monitoring capability of many brain regions.
What value proposition?: compatible to research-grade biofeedback stimuli, can be combined with EEG and eye tracking.
Product availability: as an app (software as service) for tablets, estimated to be commercially available in 1Q, 2019.
2) Digital Biomarkers = Ipsilon Cognitive Test combined with Biofeedback data analysis algorithms
We are developing machine-learning algorithms to create digital biomarkers, when biofeedback (EEG & eye tracking) devices are used together with our Ipsilon Cognitive Test.
Targeted conditions:
Dementia, Alzheimer's Disease; Attention Deficit Hyperactivity Disorder (ADHD);
Parkinson's Disease; mTBI (concussion) and CTE (chronic traumatic encephalopathy);
Schizophrenia; Pharmaceuticals' drug R&Ds for neurodegenerative diseases and evaluating their cognitive impacts.
What it does: create user's cognitive profile in comparison to Average (control group) and illness-specific biomarkers.
What do users get?: Individual cognitive data into a profile as well as risk assessment how close their responses are to illness-specific biomarkers.
What do your digital biomarkers do?: we create illness-specific biofeedback data into comparable patterns by algorithms.
What is your advantage?: Cognitive responses reveal neurological and neuropsychiatric abnormalities at much earlier stage than structural abnormalities revealed by medical imaging techniques (e.g. MRI, PET).
Side effect?: No. Non-invasive.
When available?: R&D planned for January 2019 for a year with the partnership with another startup and clinical institution, expected availability for further clinical trials in 1Q, 2020.
3) Ipsilon Cognitive Training
Using the Ipsilon Cogntitive Test with our rhythmic stimulation training, we help reduce anxiety with specific illnesses and help train visual attention.
What it does: help reduce anxiety of specific neurological and neuropsychiatric conditions. For average users, it helps increase visual attention.
What does it use?: rhythmic stimulation at specific frequency.
Any side effects?: No. Non-invasive.
How do you know its efficacy?: used together with EEG, the calming effect is confirmed by users' brainwave responses.
Target conditions: PTSD, Anxieties due to neurological and neuropsychiatric conditions mentioned in 2).
When available?: R&D planned from January 2019 for a year with the same partnership mentioned in 2). Expected to deliver in 1Q, 2020.
Our One Pager and Investor Deck are available upon request.
One-pager can be seen at Slideshare of Yayoi Sakaki, Founder and inventor.
We are in preparation for patent filing with our models and methodologies.
We are/ have been mentored at incubator/accelerator at:
HighTechXL accelerator, Eindhoven, The Netherlands (http://www.hightechxl.com/), September 4 to December 6, 2017
ENDuRE Project (University of Pisa, www.endureproject.eu/), May 30, 2016 to June 11, 2016
Erasmus Center for Entrepreneurship (http://ece.nl/), May 6, 2016 to July 1, 2016
key words: executive function, mental performance, brainwaves, dopamine, music, piano, digital therapy, sensory stimulation, connected health, cognition, cognitive wellness, mindfulness.